TMS for Inhibition Enhancement in Schizophrenia
Part of paid clinical trials in Catonsville, Maryland.
- Sponsor
- University of Maryland, Baltimore
- Study ID
- NCT06155682
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Not accepted
Interventions
- repetitive transcranial magnetic stimulation (active) — DEVICEnon-invasive active repetitive stimulation applied to the scalp surface
- repetitive transcranial magnetic stimulation (sham) — DEVICEnon-invasive active repetitive stimulation applied to the scalp surface
Study Details
This study purpose is to perform a pilot mechanistic trial repetitive transcranial magnetic stimulation (rTMS) clinical trial in 34 people with schizophrenia (Sz). The trial will evaluate whether inhibitory 1 Hertz (Hz) rTMS targeting motor cortex can increase brain inhibition reflected in a decrease in the short-interval intracortical inhibition (SICI) score from pre-to-post-treatment. We will also collect preliminary data on the effect of rTMS on the resting functional connectivity of the motor cortex and other brain regions and the relationship of change in SICI to change in cognitive performance
Key Dates
- Start date
- Feb 2, 2026
- Status verified
- Feb 2026
- Primary completion
- Mar 31, 2029
- Completion
- Apr 30, 2029
Study Design
- Enrollment
- 34 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Active Comparator: Active rTMSmultiple trains of active transcranial magnetic stimulation in a day (using the active TMS coil), for multiple days
- Sham Comparator: sham rTMSmultiple trains of sham transcranial magnetic stimulation in a day (using the sham comparator TMS coil), for multiple days
Primary Outcome Measure
The change in the short interval intracortical inhibition (SICI) score [ Time Frame: one week ]
Central Contacts
- Stephanie Hare, PhD410-402-6119
- Jennifer Zaranski
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Maryland Psychiatric Research Center | Catonsville | Maryland | 21228 |
Find similar trials in Catonsville, MD
Related Studies
- Synbiotic Compound to Reduce Symptoms of SchizophreniaPHASE2 · Recruiting · Sheppard Pratt Health System · Batlimore, Maryland
- Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaPHASE3 · Recruiting · Reviva Pharmaceuticals · Phoenix, Arizona
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical TrialPHASE4 · Recruiting · New York State Psychiatric Institute · Los Angeles, California
- An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPHASE3 · Recruiting · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phoenix, Arizona